Hybrid amyloid-beta antibodies
View Patent ↗The present invention provides crystals including amino acids 1-7 of SEQ ID NO:1 and a Fab fragment of 12A11, 12B4, 10D5 or 3D6, as well as of amino acids 1-40 of SEQ ID NO:1 and a Fab fragment of 12A11 or 3D6, as well as methods for preparing the crystals. The present invention also provides a computer implemented method for analyzing binding of a candidate antibody fragment to a peptide including an epitope of amino acids 1-7 of SEQ ID NO:1, a method for identifying an antibody fragment that can mimic the Fab fragment of 12A11, a method for identifying an antibody fragment that can mimic the Fab fragment of 3D6, a method for identifying a candidate antibody fragment that binds to a peptide including an epitope of amino acids 1-7 of SEQ ID NO:1, and a method for designing a humanized antibody that binds to a peptide comprising an epitope of amino acids 1-7 of SEQ ID NO:1.
1. An isolated antibody that binds to an epitope within residues 3-7 of Aβ, wherein CDRs L1, L2 and L3 are CDRs L1, L2 and L3 of an antibody other than 12A11 that binds to an epitope within residues 3-7 of Aβ, and CDRs H1 and H2 are CDRs H1 and H2 of the antibody other than 12A11 and CDRs L1, L2, L3, H1 and H2 of the isolated antibody differ from corresponding CDRs of 12A11 and CDR H3 is either CDR H3 of antibody 12A11 or CDR H3 of the antibody other than 12A11 modified by absence of residues X2, X3 and X4 of SEQ ID NO:28, wherein CDRs L1, L2 and L3 are CDRs L1, L2 and L3 of antibody PFA1, and CDRs H1 and H2 are CDRs H1 and H2 of antibody PFA1 and CDR H3 is CDR H3 of antibody 12A11.
2. An isolated antibody that binds to an epitope within residues 3-7 of Aβ, wherein CDRs L1, L2 and L3 are CDRs L1, L2 and L3 of an antibody other than 12A11 that binds to an epitope within residues 3-7 of Aβ, and CDRs H1 and H2 are CDRs H1 and H2 of the antibody other than 12A11 and CDRs L1, L2, L3, H1 and H2 of the isolated antibody differ from corresponding CDRs of 12A11 and CDR H3 is either CDR H3 of antibody 12A11 or CDR H3 of the antibody other than 12A11 modified by absence of residues X2, X3 and X4 of SEQ ID NO:28, wherein CDRs L1, L2 and L3 are CDRs L1, L2 and L3 of antibody PFA2, and CDRs H1 and H2 are CDRs H1 and H2 of antibody PFA2 and CDR H3 is CDR H3 of antibody 12A11.